Brief: CytRx announces positive phase 2B trial results for soft tissue sarcoma
21/09/2015 14:00
Sept 21 (Reuters) - CytRx Corp CYTR.O : * Announces the publication of its positive global phase 2b clinical trial results for soft tissue sarcoma in the peer-reviewed jama oncology * Says aldoxorubicin demonstrates significantly superior efficacy over doxorubicin * Patients treated with aldoxorubicin exhibited manageable adverse effects,had no unexpected events,did not show evidence of acute cardiotoxicity * Primary endpoint results found that subjects treated with aldoxorubicin demonstrated highly statistically significantly better clinical outcomes * Source text for Eikon ID:nPn2C9WPt * Further company coverage CYTR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C